Form 8-K CYTRX CORP For: Apr 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St set for lower open as bond yields climb; Walmart falls
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
CytRx (CYTR) Issues Update on Ongoing Aldoxorubicin Phase 2b Studies
May 4, 2015 9:04 AM EDTCytRx (NASDAQ: CYTR) announced an interim analysis from its two ongoing phase 1b aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new... More
CytRx (CYTR) Tops Q1 EPS by 52c
May 1, 2015 6:06 AM EDTCytRx (NASDAQ: CYTR) reported Q1 EPS of $0.31, $0.52 better than the analyst estimate of ($0.21).
CytRx recently appointed two new independent members to its Board of Directors. Effective April 30, 2015, Eric J. Selter, J.D. joined the Board and will serve as... More
